The DOI matches its Crossref record; 228 of the 228 references it cites were found in a registry or an index.
Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium
Open accessAbstract
The medical history of cancer began millennia ago. Historical findings of patients with cancer date back to ancient Egyptian and Greek civilizations, where this disease was predominantly treated with radical surgery and cautery that were often ineffective, leading to the death of patients. Over the centuries, important discoveries allowed to identify the biological and pathological features of tumors, without however contributing to the development of effective therapeutic approaches until the end of the 1800s, when the discovery of X-rays and their use for the treatment of tumors provided the first modern therapeutic approach in medical oncology. However, a real breakthrough took place after the Second World War, with the discovery of cytotoxic antitumor drugs and the birth of chemotherapy for the treatment of various hematological and solid tumors. Starting from this epochal turning point, there has been an exponential growth of studies concerning the use of new drugs for cancer treatment. The second fundamental breakthrough in the field of oncology and pharmacology took place at the beginning of the '80s, thanks to molecular and cellular biology studies that allowed the development of specific drugs for some molecular targets involved in neoplastic processes, giving rise to targeted therapy. Both chemotherapy and target therapy have significantly improved the survival and quality of life of cancer patients inducing sometimes complete tumor remission. Subsequently, at the turn of the third millennium, thanks to genetic engineering studies, there was a further advancement of clinical oncology and pharmacology with the introduction of monoclonal antibodies and immune checkpoint inhibitors for the treatment of advanced or metastatic tumors, for which no effective treatment was available before. Today, cancer research is always aimed at the study and development of new therapeutic approaches for cancer treatment. Currently, several researchers are focused on the development of cell therapies, anti-tumor vaccines, and new biotechnological drugs that have already shown promising results in preclinical studies, therefore, in the near future, we will certainly assist to a new revolution in the field of medical oncology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
Continuous cultures of fused cells secreting antibody of predefined specificity
KÖHLER, G., & MILSTEIN, C. (1975) · Nature · doi:10.1038/256495a0 · Cited by 17,229
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Wang, H., Naghavi, M., Allen, C., Barber, R. M., Bhutta, Z. A., Carter, A., Casey, D. C., Charlson, F. J., Chen, A. Z., Coates, M. M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31012-1 · Cited by 6,596
Global Burden of Disease Cancer Collaboration, Fitzmaurice, C., Allen, C., Barber, R. M., Barregard, L., Bhutta, Z. A., Brenner, H., Dicker, D. J., Chimed-Orchir, O., Dandona, R., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.5688 · Cited by 6,215
Cancer treatment and survivorship statistics, 2016
Miller, K. D., Siegel, R. L., Lin, C. C., Mariotto, A. B., Kramer, J. L., Rowland, J. H., Stein, K. D., Alteri, R., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21349 · Cited by 6,066
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707447 · Cited by 6,030
A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib
Kudo, M. (2017) · Liver Cancer · doi:10.1159/000462153 · Cited by 5,936
Coiffier, B., Lepage, E., Brière, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011795 · Cited by 5,574
Cited by
Anand, U., Dey, A., Chandel, A. K. S., Sanyal, R., Mishra, A., Pandey, D. K., De Falco, V., Upadhyay, A., Kandimalla, R., Chaudhary, A., et al. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2022.02.007 · Cited by 1,834
Exploring treatment options in cancer: tumor treatment strategies
Liu, B., Zhou, H., Tan, L., Siu, K. T. H., & Guan, X.-Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01856-7 · Cited by 1,201
Paclitaxel’s Mechanistic and Clinical Effects on Breast Cancer
Abu Samaan, T. M., Samec, M., Liskova, A., Kubatka, P., & Büsselberg, D. (2019) · Biomolecules · doi:10.3390/biom9120789 · Cited by 569
Sex disparities matter in cancer development and therapy
Haupt, S., Caramia, F., Klein, S. L., Rubin, J. B., & Haupt, Y. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00348-y · Cited by 331
Personalized Cancer Vaccines: Clinical Landscape, Challenges, and Opportunities
Shemesh, C. S., Hsu, J. C., Hosseini, I., Shen, B.-Q., Rotte, A., Twomey, P., Girish, S., & Wu, B. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2020.09.038 · Cited by 286
Mechanisms of Chemotherapy-Induced Neurotoxicity
Was, H., Borkowska, A., Bagues, A., Tu, L., Liu, J. Y. H., Lu, Z., Rudd, J. A., Nurgali, K., & Abalo, R. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.750507 · Cited by 285
Tinganelli, W., & Durante, M. (2020) · Cancers · doi:10.3390/cancers12103022 · Cited by 267
Three-dimensional in vitro culture models in oncology research
Jubelin, C., Muñoz-Garcia, J., Griscom, L., Cochonneau, D., Ollivier, E., Heymann, M.-F., Vallette, F. M., Oliver, L., & Heymann, D. (2022) · Cell & Bioscience · doi:10.1186/s13578-022-00887-3 · Cited by 264
Evolution of Escherichia coli Expression System in Producing Antibody Recombinant Fragments
Sandomenico, A., Sivaccumar, J. P., & Ruvo, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176324 · Cited by 134
Recent updates on innovative approaches to overcome drug resistance for better outcomes in cancer
Sharma, M., Bakshi, A. K., Mittapelly, N., Gautam, S., Marwaha, D., Rai, N., Singh, N., Tiwari, P., Agarwal, N., Kumar, A., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.04.007 · Cited by 84
Overcoming Resistance to Drugs Targeting KRAS Mutation
Jiao, D., & Yang, S. (2020) · The Innovation · doi:10.1016/j.xinn.2020.100035 · Cited by 61
The Role of Solute Carrier Transporters in Efficient Anticancer Drug Delivery and Therapy
Puris, E., Fricker, G., & Gynther, M. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020364 · Cited by 58
Clinical protein science in translational medicine targeting malignant melanoma
Gil, J., Betancourt, L. H., Pla, I., Sanchez, A., Appelqvist, R., Miliotis, T., Kuras, M., Oskolas, H., Kim, Y., Horvath, Z., et al. (2019) · Cell Biology and Toxicology · doi:10.1007/s10565-019-09468-6 · Cited by 45
Zhang, Y., Liu, X., Zhang, J., Xu, Y., Shao, J., Hu, Y., Shu, P., & Cheng, H. (2020) · Aging · doi:10.18632/aging.102929 · Cited by 37
Genc, S., Pennisi, M., Yeni, Y., Yildirim, S., Gattuso, G., Altinoz, M. A., Taghizadehghalehjoughi, A., Bolat, I., Tsatsakis, A., Hacımüftüoğlu, A., et al. (2022) · Antioxidants · doi:10.3390/antiox11071225 · Cited by 33
Self-citationTon, A.-T., Foo, J., Singh, K., Lee, J., Kalyta, A., Morin, H., Perez, C., Ban, F., Leblanc, E., Lallous, N., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052588 · Cited by 17
“Thus, we propose compound VPC-70619 as a single agent that could be effective with tolerable toxic effects within a specific therapeutic window, or as a chemotherapy agent which can be part of a combined oncogenic treatment regimen [31,32].”
Background
Metadata
- Authors
- Falzone, L., Salomone, S., & Libra, M.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2018-11-13
- Volume
- 9
- Pages
- 1300-1300
- ISSN
- 1663-9812 (ISSN-L)
- OpenAlex
- W2900960361
- Cited by
- 908
- References
- 228
- FWCI
- 50.56
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.